Keyword: Thermo Fisher Scientific
Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.
A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.
Thermo Fisher says it will put $24 million into its Scotland site on top of the $270 million it is investing in production at other sites this year.
Presented by:
Thermo Fisher Scientific
Tuesday, December 17, 2019
Cell and gene therapy transportation expert Anthony Griego, will share his key learnings resulting from working with sponsors across the cell and gene space over the past several years.
Thursday, October 10, 2019
Lupin has named a new global head of quality even as another of its plants gets an FDA Form 483.
Thermo Fisher Scientific says it will invest $270 million in its manufacturing this year from one end of the product spectrum to the other.
Presented by:
Thermo Fisher
Tuesday, October 1, 2019
Eight years after the FDA issued its guidance of process validation, some still ask the question “Is process characterization optional anymore?”
Presented by:
Patheon
Thursday, October 24, 2019
This webinar will provide an overview of Thermo Fisher Scientific’s spray-drying platform starting from early development through commercialization.
Brammer Bio is seeking tax increment financing (TIF) for a proposed new manufacturing facility in Massachusetts.
Amicus Therapeutics has struck a deal for the gene therapy units of Thermo Fisher and Catalent to handle its manufacturing.
